Skye Bioscience, Inc. SKYE 深 沪
已收盘 12-05 16:00:00 美东时间
1.20
-0.010
-0.83%
华盛通- 最 高1.2898
- 今 开1.22
- 成交量 20.09万股
- 最 低 1.18
- 昨 收 1.21
- 总市值 3718.61万
- 52周最高 5.75
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.10
- 委 比 63.19%
- 总股本 3098.84万
- 历史最高 17.6473
- 量 比 0.77
- 振 幅 9.07%
- 历史最低 1.10
- 每 手 1
- 风险率 0.95%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Insights Ahead: Skye Bioscience's Quarterly Earnings
Skye Bioscience (NASDAQ:SKYE) is set to give its latest quarterly earnings repo...
11-08 04:05
Skye Bioscience To Highlight Recent Topline Data From CBeyond, Phase 2 Proof-Of-Concept Study Of Nimacimab, Skye's Peripherally-Restricted CB1 Inhibitor Antibody, At ObesityWeek 2025
Skye Bioscience, Inc. (NASDAQ:SKYE) ("Skye"), a clinical-stage biotechnology company focused on unlocking new therapeutic pathways for obesity and other metabolic health disorders, today announced that it will present a
11-05 20:28
Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gain...
10-07 01:09
US Stocks Mixed; Dow Falls 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones index falling more th...
10-06 23:05
Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial
Skye Bioscience announced topline results from its Phase 2a CBeyond™ study of nimacimab, a CB1 inhibitor. Nimacimab monotherapy did not meet its primary weight loss endpoint, likely due to suboptimal drug exposure. However, when combined with semaglutide, nimacimab demonstrated clinically meaningful additional weight loss compared to semaglutide alone. The combination showed a favorable safety profile with no increase in gastrointestinal or neuro...
10-06 11:00
美股大行评级 | 潜在涨幅超31%！摩根大通维持通用汽车"超配"评级，目标价从60美元升至80美元
今日重点评级关注：Maxim Group：上调Adial Pharmaceuticals评级至"买入"，目标价1.5美元；BTIG：维持Climb Bio"买入"评级，目标价从7美元升至8美元
10-01 20:13
HC Wainwright & Co. Initiates Coverage On Skye Bioscience with Buy Rating, Announces Price Target of $20
HC Wainwright & Co. analyst Ananda Ghosh initiates coverage on Skye Bioscience (NASDAQ:SKYE) with a Buy rating and announces Price Target of $20.
09-30 19:22
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Enanta Pharma (NASDAQ: ENTA) stock rose 15.6% to $9.13 during Friday's after-market session. The market value of their outstanding shares is at $165.6 million.
09-27 05:06
Could This New Drug Be The Safer Way To Fight Obesity?
Skye Bioscience reported favorable Phase 1b nimacimab results, with analysts citing strong potential in obesity alongside GLP-1 therapies.
09-20 02:19
